Birch Pollen Induced Rhinitis/Rhinoconjunctivitis

1
Pipeline Programs
1
Companies
1
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
1
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

1 companies ranked by most advanced pipeline stage

Hal Allergy
Hal AllergyNetherlands - Leiden
1 program
1
SUBLIVAC FIX BirchPhase 31 trial
Active Trials
NCT02231307Completed406Est. Nov 2015

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
Hal AllergySUBLIVAC FIX Birch

Clinical Trials (1)

Total enrollment: 406 patients across 1 trials

NCT02231307Hal AllergySUBLIVAC FIX Birch

SUBLIVAC FIX Birch Phase III Short-term Efficacy

Start: Sep 2014Est. completion: Nov 2015406 patients
Phase 3Completed

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

1 late-stage (Phase 3) programs — potential near-term approvals
1 companies competing in this space